Company news

Precision BioSciences, Inc. news in 2026

Precision BioSciences, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Precision BioSciences Reports Third Quarter 2026 Financial Results and Provides Business Update

November 3, 2026

Precision BioSciences to Report Third Quarter 2026 Financial Results on November 3, 2026

October 29, 2026

Precision BioSciences Announces Late-Breaking Oral Presentation for PBGENE-HBV at AASLD The Liver Meeting 2026

October 8, 2026

Precision BioSciences Commences Dosing in Phase 1/2 FUNCTION-DMD Study

August 24, 2026

Precision BioSciences Reports Second Quarter 2026 Financial Results and Provides Business Update

August 6, 2026

Precision BioSciences to Report Second Quarter 2026 Financial Results on August 6, 2026

July 31, 2026

Precision BioSciences Announces Changes to Senior Leadership Team to Support Advancement of Programs Through Next Set of Clinical Milestones

July 27, 2026

Precision BioSciences Announces Inclusion in the Russell 2000® Index Expanding Market Visibility with Institutional Investors

June 29, 2026

Precision BioSciences Announces New and Late-Breaking PBGENE-HBV Clinical Data from the ELIMINATE-B Study at European Association for the Study of the Liver Congress 2026

May 27, 2026

Precision BioSciences to Host Investor Webcast to Discuss Late-Breaking PBGENE-HBV Data from ELIMINATE-B Trial Presented at European Association for the Study of the Liver Congress 2026

May 21, 2026

Precision BioSciences Reports First Quarter 2026 Financial Results and Provides Business Update

May 5, 2026

Precision BioSciences to Report First Quarter 2026 Financial Results on May 5, 2026

April 30, 2026

Precision BioSciences Activates First Clinical Trial Site and Begins Patient Enrollment in Phase 1/2 FUNCTION-DMD Study

April 29, 2026

Precision BioSciences Announces Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 2026 Annual Meeting

April 28, 2026

Precision BioSciences Announces Grant of Inducement Awards under Nasdaq Listing Rule 5635(4)

April 27, 2026

Precision BioSciences Announces Late-Breaking Poster Presentation for PBGENE-HBV at European Association for the Study of the Liver Congress 2026

April 22, 2026

Precision BioSciences Expands ELIMINATE-B Trial Following Clinical Trial Application Approval in Two European Countries

April 14, 2026

Precision BioSciences to Participate in the 25th Annual Needham Virtual Healthcare Conference

April 8, 2026

Precision BioSciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Business Update

March 11, 2026

Precision BioSciences Receives U.S. Patent Allowances Covering the PBGENE-HBV Program

March 10, 2026

Precision BioSciences Presents Preclinical PBGENE-DMD Data Highlighting Durable Dystrophin Expression and Functional Benefit at the Muscular Dystrophy Association Clinical & Scientific Conference 2026

March 10, 2026

Precision BioSciences Receives FDA Fast Track Designation for PBGENE-DMD and Announces Duchenne Muscular Dystrophy Investor Event

March 8, 2026

Precision BioSciences Receives $7.5M in Proceeds from TG Therapeutics for Azer-cel Clinical Milestone in Multiple Sclerosis

March 2, 2026

Precision BioSciences Announces Presentation at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference

February 18, 2026

Precision BioSciences Receives U.S. FDA Clearance of Investigational New Drug Application for First-in-Class PBGENE-DMD for Treatment of Duchenne Muscular Dystrophy

February 11, 2026

Precision BioSciences Sets Strategic Priorities for 2026 Focused on Continued Advancement of Clinical-Stage Programs PBGENE-HBV for Chronic Hepatitis B and PBGENE-DMD for Duchenne Muscular Dystrophy

January 12, 2026

Decks in 2026